BACKGROUND: There is controversy about whether breast conserving therapy (BCT) should be contraindicated in multifocal (MF) breast cancer. Few studies have reported on the oncologic safety of BCT in MF breast cancer. STUDY DESIGN: We reviewed a prospective database of 1,169 women with invasive breast cancer who were treated with segmentectomy and whole breast irradiation from 1991 through 2009 and followed at our institution. Multifocal breast cancer was defined as 2 or more distinct tumors excised with a single incision or segmentectomy. We compared 2 groups, MF and unifocal breast cancer patients, with respect to demographics, tumor characteristics, adjuvant systemic therapy, local recurrence (LR), disease-free survival (DFS), and overall survival (OS). RESULTS: One hundred sixty-four patients with MF and 999 with unifocal invasive breast cancer were treated with BCT. Median follow-up was 112 months. Compared with the unifocal group, patients in the MF group had higher 10-year LR (0.6% vs 6.1%, p < 0.001) and lower 10-year DFS (97.7% vs 89.3%, p < 0.001) and OS (98.4% vs 85.8%, p < 0.001). On multivariable analysis, multifocality was independently significantly associated with local recurrence-free survival (LRFS), DFS, and OS. CONCLUSIONS: Our data suggest that BCT in MF breast cancer is oncologically safe but may result in a slightly inferior outcome compared with BCT in unifocal breast cancer.
BACKGROUND: There is controversy about whether breast conserving therapy (BCT) should be contraindicated in multifocal (MF) breast cancer. Few studies have reported on the oncologic safety of BCT in MF breast cancer. STUDY DESIGN: We reviewed a prospective database of 1,169 women with invasive breast cancer who were treated with segmentectomy and whole breast irradiation from 1991 through 2009 and followed at our institution. Multifocal breast cancer was defined as 2 or more distinct tumors excised with a single incision or segmentectomy. We compared 2 groups, MF and unifocal breast cancerpatients, with respect to demographics, tumor characteristics, adjuvant systemic therapy, local recurrence (LR), disease-free survival (DFS), and overall survival (OS). RESULTS: One hundred sixty-four patients with MF and 999 with unifocal invasive breast cancer were treated with BCT. Median follow-up was 112 months. Compared with the unifocal group, patients in the MF group had higher 10-year LR (0.6% vs 6.1%, p < 0.001) and lower 10-year DFS (97.7% vs 89.3%, p < 0.001) and OS (98.4% vs 85.8%, p < 0.001). On multivariable analysis, multifocality was independently significantly associated with local recurrence-free survival (LRFS), DFS, and OS. CONCLUSIONS: Our data suggest that BCT in MF breast cancer is oncologically safe but may result in a slightly inferior outcome compared with BCT in unifocal breast cancer.
Authors: Francesca De Lorenzi; Francesco Borelli; Eleonora Pagan; Vincenzo Bagnardi; Nickolas Peradze; Barbara Alicia Jereczek-Fossa; Cristina Leonardi; Giovanni Mazzarol; Giorgio Favia; Giovanni Corso; Emilia Montagna; Mario Rietjens; Paolo Veronesi Journal: Ann Surg Oncol Date: 2021-10-06 Impact factor: 5.344
Authors: László Tabár; Peter B Dean; Amy M-F Yen; Miklós Tarján; Sherry Y-H Chiu; Sam L-S Chen; Jean C-Y Fann; Tony H-H Chen Journal: Breast Cancer (Auckl) Date: 2014-02-25
Authors: Nadine Norton; Pooja P Advani; Daniel J Serie; Xochiquetzal J Geiger; Brian M Necela; Bianca C Axenfeld; Jennifer M Kachergus; Ryan W Feathers; Jennifer M Carr; Julia E Crook; Alvaro Moreno-Aspitia; Panos Z Anastasiadis; Edith A Perez; E Aubrey Thompson Journal: PLoS One Date: 2016-04-14 Impact factor: 3.240
Authors: Z E Winters; J Horsnell; K T Elvers; A J Maxwell; L J Jones; A M Shaaban; P Schmid; N R Williams; A Beswick; R Greenwood; J C Ingram; C Saunders; J S Vaidya; L Esserman; I Jatoi; A M Brunt Journal: BJS Open Date: 2018-05-22
Authors: Mauro G Mastropasqua; Francesca Addante; Sara Pirola; Giuseppe Ingravallo; Giuseppe Viale Journal: Breast Date: 2020-10-17 Impact factor: 4.380